On Monday, JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 to INR3,150.00. The adjustment follows the company's third ...

Jan 23 (Reuters) - India's Mankind Pharma (MNKI.NS), opens new tab reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses. Manforce condom and Prega ...

Pharma major Mankind Pharma on Thursday reported its financial results for the third quarter and nine months ended 31 st December 2024. The company reported revenue from Operations at Rs.

Mankind Pharma (Mankind) delivered in-line operational performance for 3QFY25. The earnings were below estimates due to higher interest outgo on debt raised to fund the BSV acquisition.

Mankind Pharma Ltd, the pharmaceutical behemoth, posted its Q3 FY25 result today on January 23, 2025. The pharmaceutical giant has seen significant growth in the revenue side while the net profit ...

Shares of Mankind Pharma plunged nearly 6 percent on January 24, weighed down by a fall in the company's October-December net profit. The company's bottomline dropped over 16 percent on year in Q3 ...

So, accumulating at current levels will not make sense. Exit and accept the loss. Mankind Pharma (₹2,518.40): The long-term trend is up. Within that, the stock is in a corrective fall.

Involves transaction of at least 0.5% of the listed shares of a company. What was Mankind Pharma Ltd share price previously? Mankind Pharma Ltd share price was down by -1.13% from the previous ...

Rajeev highlighted how people from different parts of India had different preferences. Asked which is the highest-selling flavour and the lowest-selling flavour, he said 'chocolate and strawberry ...

Rajeev Juneja, managing director of Mankind Pharma, discusses the company's plans to collaborate with celebrities like Deepika Padukone and Alia Bhatt for advertisements. He praises Anushka Sharma ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...